VivoSeq
Hematology

Immune Thrombocytopenia

115

Pipeline Programs↗

68

Active Trials↗

60

Companies Involved↗

Immune Thrombocytopenia is a highly competitive landscape with 115 programs across 60 companies. The most active players are iCell Gene Therapeutics, Guangdong Hengrui Pharmaceutical Co., Ltd, Bioverativ, a Sanofi company. 9 therapies are approved with 32 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

75/100

Pipeline Velocity

54/100

Mech. Concentration

8/100

Completion Rate

73/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

iCell Gene Therapeutics

1 program

Phase 1Guangdong Hengrui Pharmaceutical Co., Ltd logo

Guangdong Hengrui Pharmaceutical Co., Ltd

1 program

Phase 1B

Bioverativ, a Sanofi company

1 program

Phase 1P

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

1 program

Phase 1Sanofi logo

Sanofi

4 programs

Phase 2GSK logo

GSK

3 programs

Phase 2

Pipeline

Programs by Phase

Preclinical16

Rituximab

Roche

Rapamycin

Maastricht Radiation Oncology

G-CSF

Arog Pharmaceuticals, Inc.

Erythropoietin

Wim Janssens

Luspatercept

Bristol-Myers Squibb

Phase 19

HMPL-523

Hutchison Medipharma Limited

Anti-CD19 CAR NK Cells

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

SHR-2173

Guangdong Hengrui Pharmaceutical Co., Ltd

PN20

Chongqing Peg-Bio Biopharm Co., Ltd.

PRG-1801

Tongji Hospital

Phase 249

Zanubrutinib

BeOne Medicines

Upadacitinib

AbbVie

Baricitinib

Eli Lilly

Belimumab

Glaxo Dba Glaxosmithkline

Dexamethasone

Aspen Global Incorporated

Phase 332

Efgartigimod

Argenx

Mycophenolate Mofetil

Roche

Rozanolixizumab

UCB

Oseltamivir

Conrado Roberto Hoffmann Filho

Mezagitamab

Takeda

Approved9

Vincristine

Eli Lilly

Hydroxychloroquine

Alnylam Pharmaceuticals

Prednisone

Roxane Laboratories

Azathioprine

Legacy Health System

Eltrombopag Combining Rituximab

Institute of Hematology & Blood Diseases Hospital, China

Analysis

Modality Breakdown

83%

Small molecule

103 of 124 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody1310%Cell therapy43%Protein / enzyme32%Peptide1<1%

Small molecule leads; the ring shows all 124 classified programs, each share of the total. Modality classified for 100% of 136 pipeline programs.

Analysis

Trial Status

183

clinical trials

Completed54 · 30%
Recruiting46 · 25%
Unknown status41 · 22%
Withdrawn11 · 6%
Active, not recruiting11 · 6%
Not yet recruiting11 · 6%
Other9 · 5%

Clinical Trials

Trial Activity

183 trials

Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia
Recruiting·—·N/A·NCT06973356·18 enrolled
The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)
Recruiting·PPeking University People's Hospital·Phase 2·NCT07065968·132 enrolled
The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia
Recruiting·SSeoul National University Hospital·Phase 2·NCT05599880·29 enrolled
Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07234019·160 enrolled
V-IMMUNE® for Immune Thrombocytopenia
Recruiting·OOn Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.·Phase 3·NCT06962631·31 enrolled
Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05338190·132 enrolled
BCMA-CD19 CCAR T Cell Treatment of Refractory Immune Thrombocytopenia Associated with Autoimmune Diseases
Recruiting·IiCell Gene Therapeutics·Phase 1·NCT06787989·20 enrolled
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06799611·20 enrolled
An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia
Recruiting·GGrand Shuyang Life Sciences (Chengdu) Co., Ltd.·Phase 3·NCT07233213·36 enrolled
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Immune Thrombocytopenia
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT05995054·110 enrolled
Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
Recruiting·CChongqing Peg-Bio Biopharm Co., Ltd.·Phase 1·NCT06880081·12 enrolled
Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06168851·60 enrolled
Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia
Recruiting·Pfizer logoPfizer·Phase 2·NCT05070845·61 enrolled
Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)
Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT07297563·160 enrolled
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia
Recruiting·NNuvig Therapeutics, Inc.·Phase 2·NCT07095127·10 enrolled
Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)